FDA Approves Brixadi, a New Treatment Option for Opioid Use Disorder
Brixadi is approved for patients with moderate-to-severe OUD who are already taking or have initiated transmucosal buprenorphine.
Source: psychiatryadvisor.com
📰 Boxed Warning News
Page 25 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...
United States Hemophagocytic Lymphohistiocytosis Satu Glawe Peter Lebowitz Obrian Kenney Data Monitoring Committee
Source: prnewswire.com
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the... | June 6, 2023
United States New Jersey Ying Huang Hemophagocytic Lymphohistiocytosis European Hematology Association Janssen Biotech Inc
Source: marketscreener.com
Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®
/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium...
Source: prnewswire.com
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®...
United States Satu Glawe Binod Dhakal Hemophagocytic Lymphohistiocytosis Legend Biotech United States Inc National Cancer Institute
Source: prnewswire.com
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
– Trodelvy – the First Trop-2-Directed ADC – Delivers a Durable and Clinically Meaningful 3.3 Month Improvement in Median Overall Survival vs. Comparator Chemotherapy in Phase 3... | June 5, 2023
United States Foster City Sara Tolaney Gilead Sciences College Of American Pathologists Gilead Sciences Inc
Source: marketscreener.com
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...
Noord Holland United States Rachel Kobos Satu Glawe Christie Corbett Eastern Cooperative Oncology Group
Source: prnewswire.com
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study... | June 5, 2023
New Jersey United States Hemophagocytic Lymphohistiocytosis European Hematology Association Janssen Biotech Inc Medicinal Devices Agency
Source: marketscreener.com
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
05.06.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 ...
United States New Jersey Mythili Koneru Hemophagocytic Lymphohistiocytosis Binod Dhakal Exchange Commission On
Source: wallstreet-online.de
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...
Source: prnewswire.com